Servify Enables Samsung Care+ for Business in Canada
Servify, a global AI-driven product ownership experience platform, announced its partnership with Samsung Electronics Canada to roll out its premium protection plan for corporate devices: Samsung Care+ for Business. The service is designed exclusively for nationwide enterprises and government customers.
After a successful launch last year in the US market where the Samsung B2B program has been well received, the partnership is now extending into the Canadian market which is poised to see more than 90 percent of Canadians becoming digital natives by 2023.*
As remote work went from “new normal” to “status quo” over the last two years, enterprises have witnessed an increased dependency on mobile devices for work and are concerned about business continuity challenges. To solve this, Samsung Care+ for Business is set to deliver a complete solution for device protection, thereby maximizing business productivity.
Servify will be responsible for overall management and administration of the program, together with system integration with Samsung’s authorized repair partners. Leveraging Servify’s post-sales product ownership experience platform, Samsung is poised to deliver protection with a combined coverage term of up to 3 years.**
|
Benefits for Enterprises |
|
|
|
“We are thrilled to have partnered with Samsung for their B2B program in Canada. Our ongoing alliance with Samsung covers several regions including US, Eastern Europe, KSA, UAE and India which reiterates the trust Samsung has in our capabilities,” said Sreevathsa Prabhakar, Founder of Servify.
“Today’s businesses are making significant investments in devices, and we believe it is our job to help them be prepared for any issues with seamless, automated device management tools. Samsung Care+ for Business, enabled by Servify’s platform and underpinned by Samsung’s authorized repair services for physical damage and liquid intrusion protection, will prove beneficial for businesses as they need to anticipate when devices are reaching end-of-life, determine if they are vulnerable to security breaches, and resolve a host of other issues before such issues create operational delays,” said Steven Cull , Head of Mobile Product Management, Services and Strategy, at Samsung Canada.
Samsung Care+ for Business provides its customers a worry-free protection plan, guaranteed Samsung certified service and hassle-free process for claims and tech support.
* https://www.statista.com/topics/4865/internet-usage-in-canada/#dossierKeyfigures
** Manufacturer's limited warranty is 1 year, plus up to 2 years of extended warranty - for a total of up to 3 years warranty. Available on certain Samsung devices, including Galaxy XCover and Tab Active Series devices. For physical damage and liquid intrusion service requests, two (2) covered claims are allowed per each 12-month period during the duration of the Samsung Care+ for Business.
About Samsung
Samsung Electronics Canada inspires Canadians to reach their full potential through a transformative ecosystem of products and services that deliver innovation and distinct design to every aspect of their connected lives. The company is redefining the worlds of TVs, smartphones and wearable devices, tablets and digital appliances. In 2022, Samsung was ranked as one of Canada's "Most Reputable Companies" in Léger's Corporate Reputation Study. Dedicated to helping make a difference in the lives of Canadians, Samsung's award-winning corporate giving initiatives support public education and health-related issues in communities across the country. To discover more, please visit www.Samsung.ca.
About Servify
Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.
Additional information on Servify is available at www.servify.tech.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005582/en/
Contact information
Debapriya Ghosh Biswas
Director - Marketing
+91-9833086156; debapriya.g@servify.tech
Rethu Panicker
Senior Manager - Corporate Communications
+91-9867181043; rethu.p@servify.tech
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom